-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Golden ophthalmology, silver surgery" can be regarded as an open secret in the medical industry, indicating the huge market value
of this segment of ophthalmology.
In recent years, with the acceleration of China's aging process, the widespread use of electronic products, and the prevalence of ophthalmic diseases such as refractive error, cataracts, and retinopathy continue to rise, and show a young age, at the same time, people's awareness of eye protection is also increasing, and the market size of ophthalmic drugs has maintained continuous growth
.
According to data from Yaorongyun, the sales of ophthalmic drugs (including chemical drugs and proprietary Chinese medicines) in the Chinese hospital market in 2021 will be 15.
197 billion yuan, a year-on-year increase of 15.
63%, which is higher than the growth rate of the overall pharmaceutical hospital market (8.
21%)
.
It can be seen that ophthalmic drugs still show a strong market demand, and the domestic ophthalmic market is constantly expanding
.
According to the report of Yaorongyun's "White Paper on the Current Status and Future Development of China's Ophthalmic Industry" (hereinafter referred to as the "Ophthalmology White Paper"), the competition pattern
of ophthalmic pharmaceutical preparations in China is hereby analyzed.
1.
TOP10 pattern of hospital generic name varieties
TOP10 pattern of hospital generic name varieties
The competition pattern data of Yaorongyun national hospital terminals (chemical drugs plus proprietary Chinese medicines) shows that the TOP10 varieties of generic famous varieties will occupy 57.
78% of the market share
in 2021.
From the perspective of market concentration, the total market share of the top four generic varieties CR4 = 35.
25%, (35% <CR4<65%) indicates that the market belongs to the medium concentration market; In 2021, CR4 increased by 2.
08 percentage points compared with CR4 in 2018, and the concentration of the top four varieties was further increased<b11>.
Combocept ranked first in 2021 with a market share of 10.
66%; In second place is ranibizumab, with a market share of 10.
17%.
The third-ranked sodium hyaluronate has a market share of 7.
61%, which has declined
in recent years.
From the perspective of sales growth rate of TOP10 products, aflocept will increase the most in 2021, followed by polyvinyl alcohol
.
2021 National Hospital Ophthalmic Drug Competition Pattern (Variety)
Image source: Yaorong Cloud "White Paper on the Status and Future Development of China's Ophthalmic Industry"
According to the Yaorong cloud database, the top ten varieties are all medical insurance catalog products, except for polyvinyl alcohol for Hunan local supplementary varieties, other products are national medical insurance varieties
.
At present, only the ophthalmic preparations of sodium hyaluronate (the fourth batch of centralized procurement) and levofloxacin (the third batch of centralized procurement) have entered the centralized procurement, and the other 8 varieties have not been included in the centralized procurement
.
2021 National Hospital Ophthalmic Drug Top Ten Varieties of Medical Insurance and Centralized Procurement
Image source: Yaorong Cloud "White Paper on the Status and Future Development of China's Ophthalmic Industry"
2.
Top 10 pattern of ophthalmic drugs in retail pharmacies
Top 10 pattern of ophthalmic drugs in retail pharmacies
The competition pattern data of pharmaceutical retail terminals (chemical drugs plus proprietary Chinese medicines) in pharmacies across the country shows that the TOP10 varieties of generic famous varieties will occupy 56.
22% of the market share
in 2021.
From the perspective of market concentration, the total market share of the top four generic varieties CR4= 28.
78%, indicating that the concentration of ophthalmic retail market is lower than that of the hospital market; Compared with CR4 in 2018, CR4 in 2021 increased by nearly 5 percentage points, and the concentration of the top four varieties increased
.
Among them, Naphthalene Minwei eye drops ranked first in 2021, with a market share of 9.
16%; In second place is sodium hyaluronate eye drops, with a market share of 8.
37%.
The third-ranked compound menton visagan eye drops has a market share of 6.
46%, which has declined
in recent years.
From the sales growth rate of TOP10 products, sodium hyaluronate eye drops increased the most in 2021, followed by levofloxacin eye drops
.
2021 Competitive Landscape of Ophthalmic Drugs in Retail Pharmacies
Image source: Yaorong Cloud "White Paper on the Status and Future Development of China's Ophthalmic Industry"
The market share of naphthalenevit eye drops has continued to lead
in recent years.
It is used to relieve symptoms
such as eye fatigue, conjunctival congestion, and itchy eyes.
This variety does not contain hormones, and has a quick effect, which is favored
by patients.
According to the China Drug Evaluation Database of Yaorongyun, up to now, the number of manufacturers declared for naphthalene minwei eye drops has reached 27, the number of applications for listing has reached 21, and 10 enterprises have been approved for production, and the competition is fierce
.
Sodium hyaluronate eye drops are used in ophthalmology for dry eye to relieve dry eye symptoms
.
Sodium hyaluronate eye drops currently account for more than 80% of dry eye drugs in China, and annual sales can reach 1 billion yuan
.
At present, the domestic approved production of sodium hyaluronate eye drops includes more than ten enterprises
such as Qilu Pharmaceutical, Yangtze River Pharmaceutical, Federal Pharmaceutical, Xinyi Jinzhu, and CP Freda.
Review of sodium hyaluronate eye drops (partial)
Image source: Yaorong Cloud China Drug Evaluation Database
3.
Major manufacturers TOP10 pattern
Major manufacturers TOP10 pattern
The competition pattern data of Yaorongyun national hospital terminals (chemical drugs plus proprietary Chinese medicines) shows that the top 10 manufacturers of ophthalmic drugs will occupy a total of 65.
31% of the market share
in 2021.
From the perspective of market concentration, the total market share of the top four manufacturers CR4 is 41.
08%, (35% < CR4<65%), indicating that the market is a medium concentration market, compared with CR4 in 2018, the concentration of the top four manufacturers has further declined
.
The total market share of the top eight manufacturers in 2021 CR8=60.
54%, (CR8<70%) indicates that the market is a low concentration oligopoly type, but CR8 in 2021 also increased by 4.
72 percentage points compared with CR8 in 2018, so the concentration of manufacturers in this field of the market has increased
.
From the perspective of the growth rate of the top 10 ophthalmic drug manufacturers, the fastest growing manufacturer in 2021 is Bayer, with an increase of 58.
51%, followed by Shenyang Xingqi, with an increase of 47.
93%.
2021 National Hospital Ophthalmic Drug Competition Pattern (Manufacturers)
Image source: Yaorong Cloud "White Paper on the Status and Future Development of China's Ophthalmic Industry"
Chengdu Kanghong Biotechnology Co.
, Ltd.
is a wholly-owned subsidiary
of Kanghong Pharmaceutical Group.
Its "Combocept Ophthalmic Injection" is a landmark product of Chinese pharmaceutical innovation, and it is also the first original Class I biological new drug
in China to obtain the WHO International Common Name (INN).
Combocept ophthalmic injection was first launched in China in March 2014, filling the market gap of domestic fundus macular degeneration treatment drugs and breaking the monopoly
of high-priced imported drugs in China's ophthalmic market.
In March 2016, Combocept ophthalmic injection was rated as "the most clinically valuable innovative drug"; In July 2017, Combocept, as a representative of domestic innovative drugs, was included in the National Medical Insurance Catalogue for the first time; In December of the same year, Combocept's PCT patent won the China Patent Gold Award
.
On December 9, 2018, the project of "Development of National Class I New Drug Combocept Ophthalmic Injection" won the highest award in China's industrial field - the fifth "China Industry Award"
.
If you want to obtain the full content of the report "White Paper on the Status and Future Development of China's Ophthalmic Industry", please pay attention to the "Yaorong Cloud" official account and reply to the "report" keyword in the background to receive
.
